(Q40204965)

18 September 2017

title

Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. (English)

1 reference

18 September 2017

2

1 reference

18 September 2017

Kurt Vermeire

3

0 references

Dominique Schols

object named as

Dominique Schols

series ordinal

5

0 references

Jan Balzarini

series ordinal

4

object named as

Jan Balzarini

1 reference

18 September 2017

Dana Huskens

1

1 reference

18 September 2017

language of work or name

English

0 references

publication date

21 November 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

360

1 reference

18 September 2017

issue

2

1 reference

18 September 2017

page(s)

294-304

1 reference

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

18 September 2017

cites work

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

A vaccine for HIV type 1: the antibody perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Reintroduction of the 2G12 epitope in an HIV-1 clade C gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Molecular Characterization of Five Neutralizing Anti-HIV Type 1 Antibodies: Identification of Nonconventional D Segments in the Human Monoclonal Antibodies 2G12 and 2F5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

HIV gp120 receptors on human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Sugar-binding proteins potently inhibit dendritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Isolation and characterization of a lectin with exclusive specificity towards mannose from snowdrop (Galanthus nivalis ) bulbs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Biosynthesis, primary structure and molecular cloning of snowdrop (Galanthus nivalis L.) lectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Characterization and molecular cloning of mannose-binding lectins from the Orchidaceae species Listera ovata, Epipactis helleborine and Cymbidium hybrid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.027

7 January 2021

10.1016/J.VIROL.2006.10.027

Identifiers

DOI

1 reference

18 September 2017

1 reference